Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients

AKAR, SERVET; Cetin, Pinar; KALYONCU, UMUT; KARADAĞ, ÖMER; SARI, İSMAİL; Cinar, Muhammed; Yilmaz, Sedat; Onat, Ahmet; Kisacik, Bunyamin; ERDEN, ABDULSAMET; Balkarli, Ayse; KÜÇÜKŞAHİN, ORHAN; Oner, Sibel; Senel, Soner; TUFAN, ABDURRAHMAN; DİRESKENELİ, RAFİ; Oksuz, Ferhat; PEHLİVAN, YAVUZ; Bayindir, Ozun; KESER, GÖKHAN; AKSU, KENAN; Omma, Ahmet; KAŞİFOĞLU, TİMUÇİN; Unal, Ali; Yildiz, Fatih; Balci, Mehmet; Yavuz, Sule; ERTEN, ŞÜKRAN; Özgen, Metin; Sayarlioglu, Mehmet; DOĞRU, Atalay; Yildirim, Gozde; Oner, Fatma; Tezcan, Mehmet; Pamuk, Omer; ÖNEN, FATOŞ

doi:10.1002/acr.23446

Nationwide Experience With Off-Label Use of Interleukin-1 Targeting Treatment in Familial Mediterranean Fever Patients

Copy For Citation

AKAR S., Cetin P., KALYONCU U., KARADAĞ Ö., SARI İ., Cinar M., ...More

ARTHRITIS CARE & RESEARCH, vol.70, no.7, pp.1090-1094, 2018 (SCI-Expanded)

Publication Type: Article / Article
Volume: 70 Issue: 7
Publication Date: 2018
Doi Number: 10.1002/acr.23446
Journal Name: ARTHRITIS CARE & RESEARCH
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.1090-1094
Ondokuz Mayıs University Affiliated: Yes

Abstract

ObjectiveApproximately 30-45% of patients with familial Mediterranean fever (FMF) have been reported to have attacks despite colchicine treatment. Currently, data on the treatment of colchicine-unresponsive or colchicine-intolerant FMF patients are limited; the most promising alternatives seem to be anti-interleukin-1 (anti-IL-1) agents. Here we report our experience with the off-label use of anti-IL-1 agents in a large group of FMF patients.